ClinicalTrials.gg
CompletedNCT01954251Updated May 2, 2018Results posted

Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older

A Phase 3 interventional study of Herpes Zoster vaccine GSK 1437173A and GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A in Herpes Zoster, sponsored by GlaxoSmithKline. Completed at 20 sites in 3 countries. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-05-02.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
829
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies testing shingrix in Herpes Zoster — 8 open to participants now, 11 under way, 3 of them phase 3. shingrix · Herpes Zoster.

Enrollment
13th of 46
829 · median 239
Started
2013
with 3 others
Phase 3
22 of 46
2 open now
Registered
11th of 46
by date
Lead sponsor
26 of 46
GlaxoSmithKline

Among the 46 studies testing shingrix in Herpes Zoster, this one is the 13th largest by enrollment, is one of 4 that started in 2013, is one of 22 in phase 3, and was the 11th registered.

Herpes Zoster

299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

8 of the 46 studies testing shingrix in Herpes Zoster are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About shingrix

shingrix: first FDA approval 2017 (Shingrix). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing shingrix in Herpes Zoster, or all of them as a file.
02

Study summary

The purpose of this study is to assess immunogenicity, reactogenicity and safety of GSK Biologicals' HZ/su vaccine when its first dose is co-administered with the FLU-D-QIV vaccine in adults aged 50 years or older compared to administration of vaccines separately.

03

Conditions studied

  • Herpes Zoster

Browse trials for

Keywords

  • FLU-D-QIV
  • Adults
  • Safety
  • Immunogenicity
  • co-administration
  • Herpes zoster
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visits).
  • A male or female aged 50 years or older, at the time of the first vaccination with the study vaccine(s).
  • Written obtained from the subject.
  • Female subjects of non- may be enrolled in the study.

    • Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or .
  • Female subjects of childbearing potential may be enrolled in the study, if the subject:

    • has practiced adequate for 30 days prior to vaccination, and
    • has a negative pregnancy test on the day of vaccination, and
    • has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series.

Exclusion criteria

Exclusion Criteria:

  • Use of any or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period.
  • Chronic administration (defined as more than 14 consecutive days) of or other immune-modifying drugs within six months prior to the first vaccine dose (for , this will mean prednisone ≥ 20 mg/day, or equivalent). A prednisone dose of \< 20 mg/day is allowed. Inhaled, topical and intra-articular corticosteroids are allowed.
  • Administration or planned administration of a vaccine not foreseen by the study protocol within the period starting 30 days before the first dose of study vaccine(s) (HZ/su and/or FLU-D-QIV vaccines) and ending 30 days after the last dose of HZ/su vaccine.
  • Administration of an influenza vaccine during the six months preceding entry into the study or planned administration up to the last blood sampling with the exception of the FLU-D-QIV vaccine given during this study.
  • Administration of long-acting immune-modifying drugs (e.g. infliximab) within six months prior to the first vaccine dose or expected administration at any time during the study period.
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product (pharmaceutical product or device).
  • Previous vaccination against VZV or HZ and/or planned administration during the study of a VZV or HZ vaccine (including an investigational or non-registered vaccine) other than the study vaccine.
  • History of HZ.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease (e.g., , infection) or immunosuppressive/cytotoxic therapy (e.g., medications used during cancer chemotherapy, organ transplantation or to treat disorders).
  • History of any reaction or likely to be exacerbated by any component of the vaccines.
  • History of Guillain Barré syndrome.
  • Hypersensitivity to latex.
  • Acute disease and/or fever at the time of enrolment.

    • Fever is defined as temperature ≥ 37.5°C /99.5°F for oral, axillary or tympanic route, or ≥ 38.0°C /100.4°F on rectal route. The preferred route for recording temperature in this study will be oral.
    • Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory infection) without fever may, be enrolled at the discretion of the investigator.
  • Administration of immunoglobulins and/or any blood products within the 3 months preceding the first dose of study vaccine or planned administration during the study period.
  • Pregnant or lactating female.
  • Female planning to become pregnant or planning to discontinue precautions before 2 months after the last dose of study vaccine.
  • Any condition which, in the opinion of the investigator, prevents the subject from participating in the study.
  • Any condition which, in the judgment of the investigator would make intramuscular injection unsafe.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
829 participants (actual)

Study arms

  • Experimental
    Co-Ad Group

    The subjects assigned to the Co-Ad group will receive one injection of the FLU-D-QIV vaccine and one injection of the HZ/su study vaccine during the first visit and a second injection of the HZ/su study vaccine during the third visit, two months later.

    Biological: Herpes Zoster vaccine GSK 1437173A · Biological: GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A

  • Active comparator
    Control Group

    The subjects assigned to the Control group will receive all vaccines separately: one injection of the FLU-D-QIV vaccine at the first visit, one injection of the HZ/su study vaccine at the third visit and a second injection of the HZ/su study vaccine at the fourth visit, all two months apart.

    Biological: Herpes Zoster vaccine GSK 1437173A · Biological: GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A

Interventions

  • 2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.

  • BiologicalGSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A

    2 doses administered intramuscularly (IM) in the deltoid region of the dominant arm.

    Also known as: Influsplit™ Tetra (Germany), Fluarix™ Quadrivalent (United States)

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Vaccine Response to Anti-gE Antibodies

    The vaccine response(VRR) for anti-gE humoral immunogenicity, as determined by enzyme-linked immunosorbent assay (ELISA),was assessed only in subjects from the GSK1437173A + GSK2321138A Group. The VRR for anti-gE was defined as the percentage of subjects who had at least: a 4-fold increase in the post-dose 2 anti-gE antibody concentration as compared to the pre-vaccination anti-gE antibody concentration, for subjects who were seropositive at baseline (cut-off ≥ 97 mIU/ml), or, a 4-fold increase in the post dose 2 anti-gE antibody concentrations as compared to the anti-gE antibodies cut-off value for seropositivity, for subjects who were seronegative at baseline (cut-off \< 97 mIU/ml).

    Time frame: At one month post-dose 2 (Month 3)

  2. Vaccine Response for Anti-gE Humoral Immunogenicity

    The vaccine response(VRR) for anti-gE humoral immunogenicity, as determined by enzyme-linked immunosorbent assay (ELISA),was assessed only in subjects from the GSK1437173A + GSK2321138A Group. The VRR for anti-gE was defined as the percentage of subjects who had at least: a 4-fold increase in the post-dose 2 anti-gE antibody concentration as compared to the pre-vaccination anti-gE antibody concentration, for subjects who were seropositive at baseline (cut-off ≥ 97 mIU/ml), or, a 4-fold increase in the post dose 2 anti-gE antibody concentrations as compared to the anti-gE antibodies cut-off value for seropositivity, for subjects who were seronegative at baseline (cut-off \< 97 mIU/ml).Criterion used: the objective was met if the Lower Limit (LL) of the 95% confidence interval (CI) of the VRR for anti-gE antibody concentrations was at least 60%.

    Time frame: At one month post-dose 2 (Month 3)

  3. Adjusted Geometric Mean ELISA Concentrations of Anti-gE Antibodies

    Geometric means (GMs) of post-vaccination concentrations (Month 3 for GSK1437173A + GSK2321138A group and Month 5 for Control group) was calculated conditionally to the means of the pre-vaccination log-transformed concentrations for anti-gE (Month 0 for GSK1437173A + GSK2321138A group and Month 2 for Control group). Adjusted Least Squares (LS) means and difference of LS means between the groups were calculated together with 2-sided 95% CIs and back-transformed to the original units to provide GMCs.

    Time frame: At one month post-dose 2 (Month 3 for GSK1437173A + GSK2321138A group and Month 5 for Control group)

  4. FLU Haemagglutination Inhibition (HI) Antibody Titers

    For each strain included in the FLU-D-QIV vaccine, an ANOVA model was used to analyze post-vaccination log-transformed titers. The fixed-effect model included the minimization variable (age cohorts) and the treatment as fixed effect. The pre-vaccination log-transformed concentrations were included as continuous covariate. Geometric Means (GM) of post-vaccination titers (Day 21) were calculated conditionally to the means of the pre-vaccination log-transformed titers (Month 0) for each strain. Adjusted GMTs (GMTs adjusted for baseline titers) and Adjusted GMT ratios were calculated together with 2-sided 95% CIs.

    Time frame: At Day 21 post vaccination

Secondary outcomes

  1. Number of Subjects With FLU HI Antibody Titers ≥1:10

    FLU HI antibodies were assessed in four strains: Flu A/California/7/2009 H1N1, Flu A/Texas/50/2012 H3N2, Flu B/Brisbane/60/2008 Victoria and Flu B/Massachusetts (Massach)/2/2012 Yamagata (Yama). Cut-off titer for seropositivity was 1:10.

    Time frame: At Day 0 (PRE) and 21 post vaccination

  2. Number of Seroprotected Subjects With HI Antibody Titers ≥ 1:40

    Seroprotection rate is defined as the percentage of vaccines with a serum HI titer ≥1:40 that usually was accepted as indicating protection. FLU HI antibodies were assessed in four strains: Flu A/California/7/2009 H1N1, Flu A/Texas/50/2012 H3N2, Flu B/Brisbane/60/2008 Victoria (Vic) and Flu B/Massachusetts(Massach)/2/2012 Yamagata (Yama).

    Time frame: At Day 0 (PRE) and at Day 21 post vaccination

  3. FLU Haemagglutination Inhibition (HI) Antibody Titers

    HI antibody titres against the four influenza vaccine strains Flu A/California/7/2009, Flu A/Texas/50/2012, Flu B/Brisbane/60/2008 Victoria (Vic) and Flu B/Massachusetts (Massach)/2/2012 Yamagata (Yamma) were expressed as geometric mean titers (GMTs).

    Time frame: At Day 0 (PRE) and Day 21 post vaccination

  4. Number of Seroconverted Subjects in Terms of HI Antibodies

    The number of seroconverted subjects was assessed in terms of HI antibodies against the four influenza vaccine strains Flu A/California/7/2009, Flu A/Texas/50/2012, Flu B/Brisbane/60/2008 Victoria and Flu B/Massachusetts/2/2012 Yamagata.

    Time frame: At Day 21 post vaccination

  5. Geometric Mean Ratio for Flu HI Antibodies Post-vaccination Titer

    The geometric mean ratio for Flu HI antibodies against the four influenza vaccine strains Flu A/California/7/2009, Flu A/Texas/50/2012, Flu B/Brisbane/60/2008 Victoria and Flu B/Massachusetts/2/2012 Yamagata was defined as the geometric mean of the within subject ratios of the post-vaccination reciprocal HI titer to the Day 0 reciprocal HI titer.

    Time frame: At Day 21 post vaccination

  6. Number of Subjects With Solicited Local Symptoms

    Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 (G3) pain = pain that prevented normal activity. Grade 3 (G3) redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. Relationship analysis was not performed.

    Time frame: Within 7 days (Days 0-6) after each vaccine dose

  7. Number of Subjects With Solicited Local Symptoms

    Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. Relationship analysis was not performed.

    Time frame: Within 7 days (Days 0-6) across doses

  8. Number of Subjects With Solicited General Symptoms

    Assessed solicited general symptoms were arthralgia, fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

    Time frame: Within 7 days (Days 0-6) after each vaccine dose

  9. Number of Subjects With Solicited General Symptoms

    Assessed solicited general symptoms were arthralgia, fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

    Time frame: Within 7 days (Days 0-6) across doses

  10. Number of Subjects With Unsolicited Adverse Events (AEs)

    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

    Time frame: During 30 days (Days 0-29) after vaccination

  11. Number of Subjects With Serious Adverse Events (SAEs)

    Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

    Time frame: From first vaccination up to Month 18 (study end)

  12. Number of Subjects With Potential Immune-mediated Diseases (pIMDs)

    pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.

    Time frame: From first vaccination up to Month 18 (study end)

07

Results

Posted Feb 10, 2016
Limitations and caveats
The current data reflect the data reported in the database at the time of the end-of-study analysis. The previous data were based on the primary analysis including a safety analysis up to the data lock point of 7-APR-2015.

Participant flow

Participant flow — Overall Study
MilestoneGSK1437173A + GSK2321138A GroupControl Group
Started413415
Completed400396
Not completed1319
Withdrew: Adverse event57
Withdrew: Lost to follow-up66
Withdrew: Withdrawal by subject26

Outcome measures

PrimaryNumber of Subjects With Vaccine Response to Anti-gE Antibodies

The vaccine response(VRR) for anti-gE humoral immunogenicity, as determined by enzyme-linked immunosorbent assay (ELISA),was assessed only in subjects from the GSK1437173A + GSK2321138A Group. The VRR for anti-gE was defined as the percentage of subjects who had at least: a 4-fold increase in the post-dose 2 anti-gE antibody concentration as compared to the pre-vaccination anti-gE antibody concentration, for subjects who were seropositive at baseline (cut-off ≥ 97 mIU/ml), or, a 4-fold increase in the post dose 2 anti-gE antibody concentrations as compared to the anti-gE antibodies cut-off value for seropositivity, for subjects who were seronegative at baseline (cut-off \< 97 mIU/ml).

Time frame:
At one month post-dose 2 (Month 3)
Reported as:
Number · Subjects
Number of Subjects With Vaccine Response to Anti-gE Antibodies
SubjectsGSK1437173A + GSK2321138A Group
Number of Subjects With Vaccine Response to Anti-gE Antibodies366
PrimaryVaccine Response for Anti-gE Humoral Immunogenicity

The vaccine response(VRR) for anti-gE humoral immunogenicity, as determined by enzyme-linked immunosorbent assay (ELISA),was assessed only in subjects from the GSK1437173A + GSK2321138A Group. The VRR for anti-gE was defined as the percentage of subjects who had at least: a 4-fold increase in the post-dose 2 anti-gE antibody concentration as compared to the pre-vaccination anti-gE antibody concentration, for subjects who were seropositive at baseline (cut-off ≥ 97 mIU/ml), or, a 4-fold increase in the post dose 2 anti-gE antibody concentrations as compared to the anti-gE antibodies cut-off value for seropositivity, for subjects who were seronegative at baseline (cut-off \< 97 mIU/ml).Criterion used: the objective was met if the Lower Limit (LL) of the 95% confidence interval (CI) of the VRR for anti-gE antibody concentrations was at least 60%.

Time frame:
At one month post-dose 2 (Month 3)
Reported as:
Number · Percentage
Vaccine Response for Anti-gE Humoral Immunogenicity
PercentageGSK1437173A + GSK2321138A Group
Vaccine Response for Anti-gE Humoral Immunogenicity95.8 (93.3 to 97.6)
PrimaryAdjusted Geometric Mean ELISA Concentrations of Anti-gE Antibodies

Geometric means (GMs) of post-vaccination concentrations (Month 3 for GSK1437173A + GSK2321138A group and Month 5 for Control group) was calculated conditionally to the means of the pre-vaccination log-transformed concentrations for anti-gE (Month 0 for GSK1437173A + GSK2321138A group and Month 2 for Control group). Adjusted Least Squares (LS) means and difference of LS means between the groups were calculated together with 2-sided 95% CIs and back-transformed to the original units to provide GMCs.

Time frame:
At one month post-dose 2 (Month 3 for GSK1437173A + GSK2321138A group and Month 5 for Control group)
Reported as:
Geometric mean · mIU/mL
Adjusted Geometric Mean ELISA Concentrations of Anti-gE Antibodies
mIU/mLGSK1437173A + GSK2321138A GroupControl Group
Adjusted Geometric Mean ELISA Concentrations of Anti-gE Antibodies52151.6 (48356.0 to 56245.2)56247.4 (52177.3 to 60634.9)
Statistical analysis
  • GSK1437173A + GSK2321138A Group vs Control Group · Adjusted geometric mean concentration ra: 1.08 · 95% CI 0.97 to 1.20
PrimaryFLU Haemagglutination Inhibition (HI) Antibody Titers

For each strain included in the FLU-D-QIV vaccine, an ANOVA model was used to analyze post-vaccination log-transformed titers. The fixed-effect model included the minimization variable (age cohorts) and the treatment as fixed effect. The pre-vaccination log-transformed concentrations were included as continuous covariate. Geometric Means (GM) of post-vaccination titers (Day 21) were calculated conditionally to the means of the pre-vaccination log-transformed titers (Month 0) for each strain. Adjusted GMTs (GMTs adjusted for baseline titers) and Adjusted GMT ratios were calculated together with 2-sided 95% CIs.

Time frame:
At Day 21 post vaccination
Reported as:
Geometric mean · Titers
FLU Haemagglutination Inhibition (HI) Antibody Titers
TitersGSK1437173A + GSK2321138A GroupControl Group
Flu A/California/7/2009 H1N1 HI Day 21187.5 (166.7 to 210.8)194.3 (173.0 to 218.1)
Flu A/Texas/50/2012 H3N2 HI Day 2163.7 (58.3 to 69.7)65.9 (60.3 to 72.0)
Flu B/Brisbane/60/2008 Victoria HI Day 21170.2 (156.1 to 185.6)181.6 (166.7 to 197.8)
Flu B/Massachusetts/2/2012 Yamagata HI Day 21423.5 (392.0 to 457.5)413.9 (383.4 to 446.8)
Statistical analysis
  • GSK1437173A + GSK2321138A Group vs Control Group · Adjusted geometric mean titer ratio: 1.04 · 95% CI 0.88 to 1.22
  • GSK1437173A + GSK2321138A Group vs Control Group · Adjusted geometric mean titer ratio: 1.03 · 95% CI 0.91 to 1.17
  • GSK1437173A + GSK2321138A Group vs Control Group · Adjusted geometric mean titer ratio: 1.07 · 95% CI 0.95 to 1.20
  • GSK1437173A + GSK2321138A Group vs Control Group · Adjusted geometric mean titer ratio: 0.98 · 95% CI 0.88 to 1.09
SecondaryNumber of Subjects With FLU HI Antibody Titers ≥1:10

FLU HI antibodies were assessed in four strains: Flu A/California/7/2009 H1N1, Flu A/Texas/50/2012 H3N2, Flu B/Brisbane/60/2008 Victoria and Flu B/Massachusetts (Massach)/2/2012 Yamagata (Yama). Cut-off titer for seropositivity was 1:10.

Time frame:
At Day 0 (PRE) and 21 post vaccination
Reported as:
Number · Subjects
Number of Subjects With FLU HI Antibody Titers ≥1:10
SubjectsGSK1437173A + GSK2321138A GroupControl Group
Flu A/California/7/2009 H1N1 Day 0 [N=386,395]288294
Flu A/California/7/2009 H1N1Day 21 [N=384,394]381389
Flu A/Texas/50/2012 H3N2 Day 0 [N=386,395]283300
Flu A/Texas/50/2012 H3N2 Day 21 [N=384,394]380392
Flu B/Brisbane/60/2008 Victoria Day 0 [N=386,395]365375
Flu B/Brisbane/60/2008 Victoria Day 21 [N=384,394]383394
Flu B/Massach/2/2012 Yama Day 0 [N=386,395]376389
Flu B/Massach/2/2012 Yama Day21 [N=384,394]384394
SecondaryNumber of Seroprotected Subjects With HI Antibody Titers ≥ 1:40

Seroprotection rate is defined as the percentage of vaccines with a serum HI titer ≥1:40 that usually was accepted as indicating protection. FLU HI antibodies were assessed in four strains: Flu A/California/7/2009 H1N1, Flu A/Texas/50/2012 H3N2, Flu B/Brisbane/60/2008 Victoria (Vic) and Flu B/Massachusetts(Massach)/2/2012 Yamagata (Yama).

Time frame:
At Day 0 (PRE) and at Day 21 post vaccination
Reported as:
Number · Subjects
Number of Seroprotected Subjects With HI Antibody Titers ≥ 1:40
SubjectsGSK1437173A + GSK2321138A GroupControl Group
Flu A/California/7/2009 H1N1 HI Day 0 [N=386,395]185161
Flu A/California/7/2009 H1N1 HI Day 21 [N=384,394]347360
Flu A/Texas/50/2012 H3N2 HI Day 0 [N=386,395]134121
Flu A/Texas/50/2012 H3N2 HI Day 21 [N=384,394]292295
Flu B/Brisbane/60/2008 Vic HI Day 0 [N=386,395]279271
Flu B/Brisbane/60/2008 Vic HI Day 21 [N=384,394]372382
Flu B/Massach/2/2012 Yama HI Day 0 [N=386,395]351361
Flu B/Massach/2/2012 Yama HI Day 21 [N=384,394]383393
SecondaryFLU Haemagglutination Inhibition (HI) Antibody Titers

HI antibody titres against the four influenza vaccine strains Flu A/California/7/2009, Flu A/Texas/50/2012, Flu B/Brisbane/60/2008 Victoria (Vic) and Flu B/Massachusetts (Massach)/2/2012 Yamagata (Yamma) were expressed as geometric mean titers (GMTs).

Time frame:
At Day 0 (PRE) and Day 21 post vaccination
Reported as:
Geometric mean · Titers
FLU Haemagglutination Inhibition (HI) Antibody Titers
TitersGSK1437173A + GSK2321138A GroupControl Group
Flu A/California/7/2009 H1N1 HI Day 0 [N=386,395]29 (25.1 to 33.5)24.9 (21.8 to 28.5)
Flu A/California/7/2009 H1N1 HI Day 21[N=384,394]196.2 (172.2 to 223.5)193.2 (170.2 to 219.4)
Flu A/Texas/50/2012 H3N2 HI Day 0 [N=386,395]19.6 (17.5 to 21.9)19.0 (17.1 to 21.1)
Flu A/Texas/50/2012 H3N2 HI Day 21 [N=384,394]65.4 (59.0 to 72.5)66.8 (60.4 to 74.0)
Flu B/Brisbane/60/2008 Vic HI Day 0 [N=386,395]52.2 (46.9 to 58.1)48.6 (43.7 to 54)
Flu B/Brisbane/60/2008 Vic HI Day 21 [N=384,394]177.2 (161.6 to 194.2)185.2 (168 to 204.1)
Flu B/Massach/2/2012 Yama HI Day 0 [N=386,395]128.8 (115.7 to 143.4)127 (114.9 to 140.3)
Flu B/Massach/2/2012 Yama HI Day 21 [N=384,394]433.7 (401.3 to 468.7)423.3 (388 to 461.8)
SecondaryNumber of Seroconverted Subjects in Terms of HI Antibodies

The number of seroconverted subjects was assessed in terms of HI antibodies against the four influenza vaccine strains Flu A/California/7/2009, Flu A/Texas/50/2012, Flu B/Brisbane/60/2008 Victoria and Flu B/Massachusetts/2/2012 Yamagata.

Time frame:
At Day 21 post vaccination
Reported as:
Number · Subjects
Number of Seroconverted Subjects in Terms of HI Antibodies
SubjectsGSK1437173A + GSK2321138A GroupControl Group
Flu A/California/7/2009 H1N1 HI232240
Flu A/Texas/50/2012 H3N2 HI136139
Flu B/Brisbane/60/2008 Victoria HI143169
Flu B/Massachusetts/2/2012 Yamagata HI154148
SecondaryGeometric Mean Ratio for Flu HI Antibodies Post-vaccination Titer

The geometric mean ratio for Flu HI antibodies against the four influenza vaccine strains Flu A/California/7/2009, Flu A/Texas/50/2012, Flu B/Brisbane/60/2008 Victoria and Flu B/Massachusetts/2/2012 Yamagata was defined as the geometric mean of the within subject ratios of the post-vaccination reciprocal HI titer to the Day 0 reciprocal HI titer.

Time frame:
At Day 21 post vaccination
Reported as:
Geometric mean · Ratio
Geometric Mean Ratio for Flu HI Antibodies Post-vaccination Titer
RatioGSK1437173A + GSK2321138A GroupControl Group
Flu A/California/7/2009 H1N1 HI6.8 (5.9 to 7.8)7.7 (6.7 to 9)
Flu A/Texas/50/2012 H3N2 HI3.4 (3.0 to 3.7)3.5 (3.2 to 4.0)
Flu B/Brisbane/60/2008 Victoria HI3.4 (3 to 3.8)3.8 (3.4 to 4.3)
Flu B/Massachusetts/2/2012 Yamagata HI3.4 (3 to 3.7)3.3 (3 to 3.7)
SecondaryNumber of Subjects With Solicited Local Symptoms

Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 (G3) pain = pain that prevented normal activity. Grade 3 (G3) redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. Relationship analysis was not performed.

Time frame:
Within 7 days (Days 0-6) after each vaccine dose
Reported as:
Number · Subjects
Number of Subjects With Solicited Local Symptoms
SubjectsGSK1437173A + GSK2321138A GroupControl Group
Any Pain D1 GSK 2321138A [N=410;412]140112
G3 Pain D1 GSK 2321138A [N=410;412]74
Any Redness D1 GSK 2321138A [N=410;412]3137
G3 Redness D1 GSK 2321138A [N=410;412]12
Any Swelling D1 GSK 2321138A [N=410;412]1618
G3 Swelling D1 GSK 2321138A [N=410;412]01
Any Pain D2 GSK 2321138A [N=0;0]NANA
G3 Pain D2 GSK 2321138A [N=0;0]NANA
Any Redness D2 GSK 2321138A [N=0;0]NANA
G3 Redness D2 GSK 2321138A [N=0;0]NANA
Any Swelling D2 GSK 2321138A [N=0;0]NANA
G3 Swelling D2 GSK 2321138A [N=0;0]NANA
Any Pain D1 GSK 1437173A [N=410;0]292NA
G3 Pain D1 GSK 1437173A [N=410;0]31NA
Any Redness D1 GSK 1437173A [N=410;0]112NA
G3 Redness D1 GSK 1437173A [N=410;0]4NA
Any Swelling D1 GSK 1437173A [N=410;0]64NA
G3 Swelling D1 GSK 1437173A [N=410;0]0NA
Any Pain D2 GSK 1437173A [N=403;405]290280
G3 Pain D2 GSK 1437173A [N=403;405]3225
Any Redness D2 GSK 1437173A [N=403;405]10391
G3 Redness D2 GSK 1437173A [N=403;405]56
Any Swelling D2 GSK 1437173A [N=403;405]6447
G3 Swelling D2 GSK 1437173A [N=403;405]00
Any Pain D3 GSK 2321138A [N=0;0]NANA
G3 Pain D3 GSK 2321138A [N=0;0]NANA
Any Redness D3 GSK 2321138A [N=0;0]NANA
G3 Redness D3 GSK 2321138A [N=0;0]NANA
Any Swelling D3 GSK 2321138A [N=0;0]NANA
G3 Swelling D3 GSK 2321138A [N=0;0]NANA
Any Pain D3 GSK 1437173A [N=0;402]NA269
G3 Pain D3 GSK 1437173A [N=0;402]NA25
Any Redness D3 GSK 1437173A [N=0;402]NA100
G3 Redness D3 GSK 1437173A [N=0;402]NA7
Any Swelling D3 GSK 1437173A [N=0;402]NA50
G3 Swelling D2 GSK 1437173A [N=0;402]NA4
SecondaryNumber of Subjects With Solicited Local Symptoms

Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. Relationship analysis was not performed.

Time frame:
Within 7 days (Days 0-6) across doses
Reported as:
Number · Subjects
Number of Subjects With Solicited Local Symptoms
SubjectsGSK1437173A + GSK2321138A GroupControl Group
Any Pain Across Doses344318
Grade 3 Pain Across Doses5540
Any Redness Across Doses153144
Grade 3 Redness Across Doses914
Any Swelling Across Doses9986
Grade 3 Swelling Across Doses05
SecondaryNumber of Subjects With Solicited General Symptoms

Assessed solicited general symptoms were arthralgia, fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

Time frame:
Within 7 days (Days 0-6) after each vaccine dose
Reported as:
Number · Subjects
Number of Subjects With Solicited General Symptoms
SubjectsGSK1437173A + GSK2321138A Group
Any Arthralgia Dose 1 [N=409]89
Grade 3 Arthralgia Dose 1 [N=409]8
Related Arthralgia Dose 1 [N=409]67
Any Fatigue Dose 1 [N=409]150
Grade 3 Fatigue Dose 1 [N=409]15
Related Fatigue Dose 1 [N=409]107
Any Gastrointestinal Dose 1 [N=409]57
Grade 3 Gastrointestinal Dose 1 [N=409]5
Related Gastrointestinal Dose 1 [N=409]28
Any Headache Dose 1 [N=409]122
Grade 3 Headache Dose 1 [N=409]5
Related Headache Dose 1 [N=409]80
Any Myalgia Dose 1 [N=409]135
Grade 3 Myalgia Dose 1 [N=409]11
Related Myalgia Dose 1 [N=409]105
Any Shivering Dose 1 [N=409]101
Grade 3 Shivering Dose 1 [N=409]12
Related Shivering Dose 1 [N=409]86
Any Temperature Dose 1 [N=409]63
Grade 3 Temperature Dose 1 [N=409]1
Related Temperature Dose 1 [N=409]53
Any Arthralgia Dose 2 [N=402]114
Grade 3 Arthralgia Dose 2 [N=402]16
Related Arthralgia Dose 2 [N=402]94
Any Fatigue Dose 2 [N=402]167
Grade 3 Fatigue Dose 2 [N=402]23
Related Fatigue Dose 2 [N=402]138
Any Gastrointestinal Dose 2 [N=402]47
Grade 3 Gastrointestinal Dose 2 [N=402]3
Related Gastrointestinal Dose 2 [N=402]32
Any Headache Dose 2 [N=402]136
Grade 3 Headache Dose 2 [N=402]16
Related Headache Dose 2 [N=402]109
Any Myalgia Dose 2 [N=402]157
Grade 3 Myalgia Dose 2 [N=402]18
Related Myalgia Dose 2 [N=402]135
Any Shivering Dose 2 [N=402]142
Grade 3 Shivering Dose 2 [N=402]30
Related Shivering Dose 2 [N=402]122
Any Temperature Dose 2 [N=402]74
Grade 3 Temperature Dose 2 [N=402]1
Related Temperature Dose 2 [N=402]63
SecondaryNumber of Subjects With Solicited General Symptoms

Assessed solicited general symptoms were arthralgia, fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

Time frame:
Within 7 days (Days 0-6) after each vaccine dose
Reported as:
Number · Subjects
Number of Subjects With Solicited General Symptoms
SubjectsControl Group
Any Arthralgia, Dose 1 [N=411]37
Grade 3 Arthralgia, Dose 1 [N=411]8
Related Arthralgia, Dose 1 [N=411]25
Any Fatigue, Dose 1 [N=411]52
Grade 3 Fatigue, Dose 1 [N=411]4
Related Fatigue, Dose 1 [N=411]33
Any Gastrointestinal, Dose 1 [N=411]32
Grade 3 Gastrointestinal, Dose 1 [N=411]2
Related Gastrointestinal, Dose 1 [N=411]16
Any Headache, Dose 1 [N=411]57
Grade 3 Headache, Dose 1 [N=411]2
Related Headache, Dose 1 [N=411]31
Any Myalgia, Dose 1 [N=411]55
Grade 3 Myalgia, Dose 1 [N=411]4
Related Myalgia, Dose 1 [N=411]45
Any Shivering, Dose 1 [N=411]30
Grade 3 Shivering, Dose 1 [N=411]0
Related Shivering, Dose 1 [N=411]25
Any Temperature, Dose 1 [N=411]18
Grade 3 Temperature, Dose 1 [N=411]0
Related Temperature, Dose 1 [N=411]15
Any Arthralgia, Dose 2 [N=405]67
Grade 3 Arthralgia, Dose 2 [N=405]6
Related Arthralgia, Dose 2 [N=405]51
Any Fatigue, Dose 2 [N=405]108
Grade 3 Fatigue, Dose 2 [N=405]9
Related Fatigue, Dose 2 [N=405]87
Any Gastrointestinal, Dose 2 [N=405]37
Grade 3 Gastrointestinal, Dose 2 [N=405]1
Related Gastrointestinal, Dose 2 [N=405]28
Any Headache, Dose 2 [N=405]87
Grade 3 Headache, Dose 2 [N=405]8
Related Headache, Dose 2 [N=405]70
Any Myalgia, Dose 2 [N=405]135
Grade 3 Myalgia, Dose 2 [N=405]7
Related Myalgia, Dose 2 [N=405]115
Any Shivering, Dose 2 [N=405]87
Grade 3 Shivering, Dose 2 [N=405]10
Related Shivering, Dose 2 [N=405]75
Any Temperature, Dose 2 [N=405]44
Grade 3 Temperature, Dose 2 [N=405]1
Related Temperature, Dose 2 [N=405]34
Any Arthralgia, Dose 3 [N=402]95
Grade 3 Arthralgia, Dose 3 [N=402]18
Related Arthralgia, Dose 3 [N=402]79
Any Fatigue, Dose 3 [N=402]149
Grade 3 Fatigue, Dose 3 [N=402]31
Related Fatigue, Dose 3 [N=402]120
Any Gastrointestinal, Dose 3 [N=402]63
Grade 3 Gastrointestinal, Dose 3 [N=402]6
Related Gastrointestinal, Dose 3 [N=402]46
Any Headache, Dose 3 [N=402]133
Grade 3 Headache, Dose 3 [N=402]23
Related Headache, Dose 3 [N=402]111
Any Myalgia, Dose 3 [N=402]138
Grade 3 Myalgia, Dose 3 [N=402]24
Related Myalgia, Dose 3 [N=402]121
Any Shivering, Dose 3 [N=402]147
Grade 3 Shivering, Dose 3 [N=402]23
Related Shivering, Dose 3 [N=402]131
Any Temperature, Dose 3 [N=402]87
Grade 3 Temperature, Dose 3 [N=402]2
Related Temperature, Dose 3 [N=402]70
SecondaryNumber of Subjects With Solicited General Symptoms

Assessed solicited general symptoms were arthralgia, fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

Time frame:
Within 7 days (Days 0-6) across doses
Reported as:
Number · Subjects
Number of Subjects With Solicited General Symptoms
SubjectsGSK1437173A + GSK2321138A GroupControl Group
Any Arthralgia, Across Doses154135
Grade 3 Arthralgia, Across Doses2324
Related Arthralgia, Across Doses121110
Any Fatigue, Across Doses224186
Grade 3 Fatigue, Across Doses3038
Related Fatigue, Across Doses175151
Any Gastrointestinal, Across Doses9092
Grade 3 Gastrointestinal, Across Doses69
Related Gastrointestinal, Across Doses4966
Any Headache, Across Doses183170
Grade 3 Headache, Across Doses2028
Related Headache, Across Doses140142
Any Myalgia, Across Doses201201
Grade 3 Myalgia, Across Doses2730
Related Myalgia, Across Doses167177
Any Shivering, Across Doses174181
Grade 3 Shivering, Across Doses3530
Related Shivering, Across Doses151159
Any Temperature, Across Doses107119
Grade 3 Temperature, Across Doses23
Related Temperature, Across Doses9096
SecondaryNumber of Subjects With Unsolicited Adverse Events (AEs)

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

Time frame:
During 30 days (Days 0-29) after vaccination
Reported as:
Number · Subjects
Number of Subjects With Unsolicited Adverse Events (AEs)
SubjectsGSK1437173A + GSK2321138A GroupControl Group
Any AEs110162
Grade 3 AEs1729
Related AEs1826
SecondaryNumber of Subjects With Serious Adverse Events (SAEs)

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Time frame:
From first vaccination up to Month 18 (study end)
Reported as:
Number · Subjects
Number of Subjects With Serious Adverse Events (SAEs)
SubjectsGSK1437173A + GSK2321138A GroupControl Group
Number of Subjects With Serious Adverse Events (SAEs)4239
SecondaryNumber of Subjects With Potential Immune-mediated Diseases (pIMDs)

pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.

Time frame:
From first vaccination up to Month 18 (study end)
Reported as:
Number · Subjects
Number of Subjects With Potential Immune-mediated Diseases (pIMDs)
SubjectsGSK1437173A + GSK2321138A GroupControl Group
Number of Subjects With Potential Immune-mediated Diseases (pIMDs)42

Adverse events

Collected over Systematically-assessed symptoms: Days 0-7 post each vaccine dose; AEs: Days 0-29 post each vaccine dose; SAEs: from Day 0 to Month 18. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GSK1437173A + GSK2321138A Group—42/413 (10.2%)370/413 (89.6%)
Control Group—39/415 (9.4%)369/415 (88.9%)
Most frequent serious events
Showing 10 of 91
Most frequent serious events
EventGSK1437173A + GSK2321138A GroupControl Group
Coronary artery diseaseCardiac disorders3/4131/415
Cerebrovascular accidentNervous system disorders3/4130/415
PneumoniaInfections and infestations3/4130/415
OsteoarthritisMusculoskeletal and connective tissue disorders1/4133/415
SyncopeNervous system disorders2/4131/415
Angina unstableCardiac disorders2/4130/415
UrosepsisInfections and infestations2/4130/415
Atrial fibrillationCardiac disorders1/4132/415
HypertensionVascular disorders1/4132/415
PancreatitisGastrointestinal disorders0/4132/415
Most frequent other events
Showing 10 of 11
Most frequent other events
EventGSK1437173A + GSK2321138A GroupControl Group
PainGeneral disorders344/411318/413
FatigueGeneral disorders224/411186/413
MyalgiaGeneral disorders201/411201/413
HeadacheGeneral disorders183/411170/413
ShiveringGeneral disorders174/411181/413
ArthralgiaGeneral disorders154/411135/413
RednessGeneral disorders153/411144/413
Temperature/(Oral)General disorders107/411119/413
SwellingGeneral disorders99/41186/413
GastrointestinalGeneral disorders90/41192/413

Baseline characteristics

Age, Continuous
Age, Continuous(Years)GSK1437173A + GSK2321138A GroupControl GroupTotal
Mean63.4 ± 8.363.4 ± 8.863.4 ± 8.55
Sex: Female, Male
Sex: Female, Male(Participants)GSK1437173A + GSK2321138A GroupControl GroupTotal
Female211218429
Male202197399
08

Study locations

20 sites
  • GSK Investigational Site
    Phoenix, Arizona 85018, United States
  • GSK Investigational Site
    Carnegie, Pennsylvania 15106, United States
  • GSK Investigational Site
    Erie, Pennsylvania 16508, United States
  • GSK Investigational Site
    Brampton, Ontario L6T 0G1, Canada
  • GSK Investigational Site
    Toronto, Ontario M9W 4L6, Canada
  • GSK Investigational Site
    Weinheim, Baden-Wuerttemberg 69469, Germany
  • GSK Investigational Site
    Wuerzburg, Bayern 97070, Germany
  • GSK Investigational Site
    Floersheim, Hessen 65439, Germany
  • GSK Investigational Site
    Essen, Nordrhein-Westfalen 45355, Germany
  • GSK Investigational Site
    Goch, Nordrhein-Westfalen 47574, Germany
  • GSK Investigational Site
    Dippoldiswalde, Sachsen 01744, Germany
  • GSK Investigational Site
    Freiberg, Sachsen 09599, Germany
  • GSK Investigational Site
    Freital, Sachsen 01705, Germany
  • GSK Investigational Site
    Luebeck, Schleswig-Holstein 23554, Germany
  • GSK Investigational Site
    Berlin, 10117, Germany
  • GSK Investigational Site
    Berlin, 10629, Germany
  • GSK Investigational Site
    Berlin, 10717, Germany
  • GSK Investigational Site
    Berlin, 10787, Germany
  • GSK Investigational Site
    Berlin, 13125, Germany
  • GSK Investigational Site
    Berlin, 13347, Germany
09

References and documents

Publications

  • Schwarz TF, Aggarwal N, Moeckesch B, Schenkenberger I, Claeys C, Douha M, Godeaux O, Grupping K, Heineman TC, Fauqued ML, Oostvogels L, Van den Steen P, Lal H. Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine Coadministered With Seasonal Influenza Vaccine in Adults Aged 50 Years or Older. J Infect Dis. 2017 Dec 12;216(11):1352-1361. doi: 10.1093/infdis/jix481. PubMed 29029224 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2013, a primary completion of Jun 2014 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2016, 1 year 8 months after primary completion. A results delay was requested in Jun 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2013
First posted
Oct 1, 2013
Start
Oct 3, 2013
Primary completionActual
Jun 2, 2014
CompletionActual
Mar 20, 2015
Results delay requested
Jun 25, 2015
Results first posted
Feb 10, 2016
Last update
May 2, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 2, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01954251
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 1, 2013
Start date
Oct 3, 2013
Primary completion
Jun 2, 2014
Completion
Mar 20, 2015
Results posted
Feb 10, 2016
Last update
May 2, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Shingrix

Start the discussion